Ocular Therapeutics Sustained Release TKI Trial
We review the current status of the Ocular Therapeutics TKI sustained release delivery system for treatment of neovascular AMD with Dr. Andrew Moshfeghi, Associate Professor of Ophthalmology USC Roski Eye Institute.